(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares of the company rose 3.6 ...
(Reuters) -Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and plans to increase production of its weight-loss treatment Zepbound and related diabetes drug ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and a steady ramp up of production of its weight-loss treatment Zepbound and related diabetes drug Mounjaro, ...
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly (NYSE:LLY)'s weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday ...
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly (NYSE: LLY )'s weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, ...
Farmaceutica, 65 anni di storia in Italia: a Eli Lilly il... Per "lo storico impegno nell’ambito della ricerca, sviluppo e produzione di farmaci innovativi in Italia, dove da 65 anni ha sede, ...